


HEALTHCARE

Pharmaceutical Strategic Alliances

Benchmarking 21st century deal-making

By Steven Seget

 [Table of Contents](#)

Steven Seget

Steven Seget is the Director of Delphi Pharma, and provides independent strategic consulting services to the pharmaceutical and biotechnology industries. Steven previously managed the strategic healthcare consulting function at Datamonitor and graduated from the London School of Economics in Accounting & Finance. **Error! Hyperlink reference not valid.**

Delphi Pharma provides strategic, financial and market-based solutions to clients, focusing primarily on the business development and licensing functions. Delphi Pharma combines an extensive research network, applied analytical expertise and an established track record to deliver high value results and measurable impact to its clients. **Error! Hyperlink reference not valid.**

Copyright © 2002 Business Insights Ltd

This Management Report is published by Business Insights Ltd. All rights reserved. Reproduction or redistribution of this Management Report in any form for any purpose is expressly prohibited without the prior consent of Business Insights Ltd.

The views expressed in this Management Report are those of the publisher, not of Business Insights. Business Insights Ltd accepts no liability for the accuracy or completeness of the information, advice or comment contained in this Management Report nor for any actions taken in reliance thereon.

While information, advice or comment is believed to be correct at the time of publication, no responsibility can be accepted by Business Insights Ltd for its completeness or accuracy.

Printed and bound in Great Britain by MBA Group Limited, MBA House, Garman Road, London N17 0HW. www.mba-group.com

Table of Contents

Pharmaceutical Strategic Alliances *Benchmarking 21st century deal-making*

Executive Summary	16	
21 st Century Alliances	16	
Trends by Alliance Type	17	
Trends by Therapy Area	18	
Trends by Technology	19	
Trends by Company Type	20	
Key Future Trends and Take Aways	21	
Chapter 1	21st Century Alliances	24
Summary		24
Introduction		25
Methodology		25
Sources		25
Definitions		26
Structure		27
Alliance trends		28
Number of deals		28
Relationship vs. transaction		29
Alliance value		30
Relationship alliance value		32
Transaction alliance value		45
Company type		48
Strategic Alliances		51
Chapter 2	Trends by Alliance Type	54
Summary		54
Introduction		55
Methodology		55
Overall Results		57

Technology vs. therapy area	57
Stage of alliance	58
Level of collaboration	58
Deal value	59
Acquisition	60
Key deals by value	61
Key companies	63
Company type	64
Development stage	65
Other deal terms	65
Therapy area	66
Technology	66
Transaction Licensing	67
Key deals by value	67
Key companies	69
Company type	70
Development stage	70
Other deal terms	71
Therapy area	72
Technology	73
Relationship Licensing	73
Key deals by value	74
Key companies	75
Company type	76
Development stage	77
Other deal terms	77
Therapy area	78
Technology	79
Co-development	79
Key deals by value	80
Key companies	82
Company type	83
Development stage	84
Other deal terms	84
Therapy area	85
Technology	86
Co-commercialization	86
Key deals by value	87
Key companies	89
Company type	90
Development stage	90
Other deal terms	91
Therapy area	91
Technology	92
Other Alliance Types	92
Key deals by value	93

Chapter 3 Trends by Therapy Area 96

Summary	96
Introduction	97
Methodology	97
Overall Results	98
Key therapy areas	99
Deal value	100
Key deals by value	101
Key companies	102
Company type	102
Level of collaboration	103
Development stage	104
Technology	104
Oncology	105
Key deals by value	105
Key companies	107
Company type	108
Level of collaboration	108
Development stage	109
Technology	109
Infectious & Viral Diseases	110
Key deals by value	110
Key companies	112
Company type	112
Level of collaboration	113
Development stage	114
Technology	114
Central Nervous System	115
Key deals by value	115
Key companies	117
Company type	117
Level of collaboration	118
Development stage	119
Technology	119
Cardiovascular	120
Key deals by value	120
Key companies	122
Company type	123
Level of collaboration	123
Development stage	124
Technology	124
Musculoskeletal & Inflammation	125
Key deals by value	125
Key companies	127
Company type	127
Level of collaboration	128
Development stage	128

Technology	129
Metabolic	129
Key deals by value	130
Key companies	132
Company type	132
Level of collaboration	133
Development stage	134
Technology	134
Vaccines	135
Key deals by value	135
Key companies	136
Company type	137
Level of collaboration	137
Development stage	138
Technology	138
Therapy area	139
Diagnostics	139
Key deals by value	140
Key companies	141
Company type	142
Level of collaboration	142
Development stage	143
Technology	143
Therapy area	144
Equipment & Devices	144
Key deals by value	145
Key companies	147
Company type	147
Level of collaboration	148
Development stage	148
Technology	149
Therapy area	149
Other Therapy Areas	150
Key deals by value	151

Chapter 4 Trends by Technology 153

Summary	153
Introduction	154
Methodology	154
Overall Results	155
Key technologies	155
Deal value	156
Key deals by value	157
Key companies	158
Company type	159
Level of collaboration	160

Development stage	160
Therapy area	161
Genomics	161
Key deals by value	162
Key companies	164
Company type	164
Level of collaboration	165
Development stage	165
Therapy area	166
Standard Platforms	166
Key deals by value	167
Key companies	168
Company type	169
Level of collaboration	169
Development stage	170
Therapy area	170
Drug Delivery	171
Key deals by value	171
Key companies	172
Company type	173
Level of collaboration	174
Development stage	175
Therapy area	176
Proteomics	176
Key deals by value	177
Key companies	179
Company type	180
Level of collaboration	180
Development stage	181
Therapy area	181
Bioinformatics	182
Key deals by value	182
Key companies	184
Company type	184
Level of collaboration	185
Development stage	185
Therapy area	186
Gene/Cell Therapy	186
Key deals by value	187
Key companies	189
Company type	190
Level of collaboration	190
Development stage	191
Therapy area	191
Pharmacogenomics	192
Key companies	192
Company type	193
Level of collaboration	193
Development stage	194
Therapy area	194

Other Technology	195
Key deals by value	195
Chapter 5	Trends by Company Type
	197
Summary	197
Introduction	198
Methodology	198
Overall Results	199
Key companies	199
Company type	200
Partnership type	201
Deal value	202
Pharmaceutical/Pharmaceutical	203
Key deals by value	204
Key companies	205
Level of collaboration	205
Development stage	206
Therapy area	207
Technology	207
Pharmaceutical/Biotechnology	208
Key deals by value	209
Key companies	211
Level of collaboration	213
Development stage	214
Therapy area	215
Technology	216
Biotechnology/Biotechnology	216
Key deals by value	217
Key companies	218
Level of collaboration	219
Development stage	220
Therapy area	221
Technology	222
Drug Delivery	222
Key deals by value	223
Key companies	225
Company type	226
Level of collaboration	227
Development stage	228
Therapy area	229
Technology	230
Academia/NGO	230
Key deals by value	231
Key companies	233
Company type	234
Level of collaboration	235

Glossary	271
Index	277

List of Figures

Figure 1.1:	Total number of alliances 2000Q1-2002Q2	28
Figure 1.2:	Relationship vs. transaction alliances 2000Q1-2002Q2	29
Figure 1.3:	Equity and joint venture alliances 2000Q1-2002Q2	30
Figure 1.4:	Average and maximum alliance value, 2000Q1-2002Q2	31
Figure 1.5:	Alliance deal-making companies, 2000Q1-2002Q2	49
Figure 1.6:	Alliances by company type, 2000Q1-2002Q2	51
Figure 2.7:	Technology vs. therapy area, 2001Q3-2002Q2	57
Figure 2.8:	Stage of alliance, 2001Q3-2002Q2	58
Figure 2.9:	Level of collaboration, 2001Q3-2002Q2	59
Figure 2.10:	Average deal value by level of collaboration, 2001Q3-2002Q2	60
Figure 2.11:	Acquisition - key companies, 2001Q3-2002Q2	63
Figure 2.12:	Acquisition - deal-making by company type, 2001Q3-2002Q2	64
Figure 2.13:	Acquisition - stage of alliance, 2001Q3-2002Q2	65
Figure 2.14:	Acquisition - other deal terms, 2001Q3-2002Q2	65
Figure 2.15:	Acquisition - therapy area, 2001Q3-2002Q2	66
Figure 2.16:	Acquisition - technology, 2001Q3-2002Q2	66
Figure 2.17:	Transaction licensing - key companies, 2001Q3-2002Q2	69
Figure 2.18:	Transaction licensing - deal-making by company type, 2001Q3-2002Q2	70
Figure 2.19:	Transaction licensing - stage of alliance, 2001Q3-2002Q2	70
Figure 2.20:	Transaction licensing - other deal terms, 2001Q3-2002Q2	71
Figure 2.21:	Transaction licensing - therapy area, 2001Q3-2002Q2	72
Figure 2.22:	Transaction licensing - technology, 2001Q3-2002Q2	73
Figure 2.23:	Relationship licensing - key companies, 2001Q3-2002Q2	75
Figure 2.24:	Relationship licensing - deal-making by company type, 2001Q3-2002Q2	76
Figure 2.25:	Relationship licensing - stage of alliance, 2001Q3-2002Q2	77
Figure 2.26:	Relationship licensing - other deal terms, 2001Q3-2002Q2	77
Figure 2.27:	Relationship licensing - therapy area, 2001Q3-2002Q2	78
Figure 2.28:	Relationship licensing - technology, 2001Q3-2002Q2	79
Figure 2.29:	Co-development - key companies, 2001Q3-2002Q2	82
Figure 2.30:	Co-development - deal-making by company type, 2001Q3-2002Q2	83
Figure 2.31:	Co-development - stage of alliance, 2001Q3-2002Q2	84
Figure 2.32:	Co-development - other deal terms, 2001Q3-2002Q2	84
Figure 2.33:	Co-development - therapy area, 2001Q3-2002Q2	85
Figure 2.34:	Co-development - technology, 2001Q3-2002Q2	86
Figure 2.35:	Co-marketing vs. co-promotion, 2001Q3-2002Q2	87
Figure 2.36:	Co-commercialization - key companies, 2001Q3-2002Q2	89
Figure 2.37:	Co-commercialization - deal-making by company type, 2001Q3-2002Q2	90
Figure 2.38:	Co-commercialization - stage of alliance, 2001Q3-2002Q2	90
Figure 2.39:	Co-commercialization - other deal terms, 2001Q3-2002Q2	91
Figure 2.40:	Co-commercialization - therapy area, 2001Q3-2002Q2	91
Figure 2.41:	Co-commercialization - technology, 2001Q3-2002Q2	92

Figure 2.42:	Other alliance types, 2001Q3-2002Q2	93
Figure 3.43:	Key therapy areas, 2001Q3-2002Q2	99
Figure 3.44:	Average deal value by therapy area, 2001Q3-2002Q2	100
Figure 3.45:	Therapy area - key companies, 2001Q3-2002Q2	102
Figure 3.46:	Therapy area - deal-making by company type, 2001Q3-2002Q2	102
Figure 3.47:	Therapy area – level of collaboration, 2001Q3-2002Q2	103
Figure 3.48:	Therapy area - stage of alliance, 2001Q3-2002Q2	104
Figure 3.49:	Therapy area - technology, 2001Q3-2002Q2	104
Figure 3.50:	Oncology - key companies, 2001Q3-2002Q2	107
Figure 3.51:	Oncology - deal-making by company type, 2001Q3-2002Q2	108
Figure 3.52:	Oncology – level of collaboration, 2001Q3-2002Q2	108
Figure 3.53:	Oncology - stage of alliance, 2001Q3-2002Q2	109
Figure 3.54:	Oncology - technology, 2001Q3-2002Q2	109
Figure 3.55:	Infectious & viral diseases - key companies, 2001Q3-2002Q2	112
Figure 3.56:	Infectious & viral diseases - deal-making by company type, 2001Q3-2002Q2	112
Figure 3.57:	Infectious & viral diseases – level of collaboration, 2001Q3-2002Q2	113
Figure 3.58:	Infectious & viral diseases - stage of alliance, 2001Q3-2002Q2	114
Figure 3.59:	Infectious & viral diseases - technology, 2001Q3-2002Q2	114
Figure 3.60:	Central nervous system - key companies, 2001Q3-2002Q2	117
Figure 3.61:	Central nervous system - deal-making by company type, 2001Q3-2002Q2	117
Figure 3.62:	Central nervous system – level of collaboration, 2001Q3-2002Q2	118
Figure 3.63:	Central nervous system - stage of alliance, 2001Q3-2002Q2	119
Figure 3.64:	Central nervous system - technology, 2001Q3-2002Q2	119
Figure 3.65:	Cardiovascular - key companies, 2001Q3-2002Q2	122
Figure 3.66:	Cardiovascular - deal-making by company type, 2001Q3-2002Q2	123
Figure 3.67:	Cardiovascular – level of collaboration, 2001Q3-2002Q2	123
Figure 3.68:	Cardiovascular - stage of alliance, 2001Q3-2002Q2	124
Figure 3.69:	Cardiovascular - technology, 2001Q3-2002Q2	124
Figure 3.70:	Musculoskeletal & inflammation - key companies, 2001Q3-2002Q2	127
Figure 3.71:	Musculoskeletal & inflammation - deal-making by company type, 2001Q3-2002Q2	127
Figure 3.72:	Musculoskeletal & inflammation – level of collaboration, 2001Q3-2002Q2	128
Figure 3.73:	Musculoskeletal & inflammation - stage of alliance, 2001Q3-2002Q2	128
Figure 3.74:	Musculoskeletal & inflammation - technology, 2001Q3-2002Q2	129
Figure 3.75:	Metabolic - key companies, 2001Q3-2002Q2	132
Figure 3.76:	Metabolic - deal-making by company type, 2001Q3-2002Q2	132
Figure 3.77:	Metabolic – level of collaboration, 2001Q3-2002Q2	133
Figure 3.78:	Metabolic - stage of alliance, 2001Q3-2002Q2	134
Figure 3.79:	Metabolic - technology, 2001Q3-2002Q2	134
Figure 3.80:	Vaccines - key companies, 2001Q3-2002Q2	136
Figure 3.81:	Vaccines - deal-making by company type, 2001Q3-2002Q2	137
Figure 3.82:	Vaccines – level of collaboration, 2001Q3-2002Q2	137
Figure 3.83:	Vaccines - stage of alliance, 2001Q3-2002Q2	138
Figure 3.84:	Vaccines - technology, 2001Q3-2002Q2	138
Figure 3.85:	Vaccines – therapy areas, 2001Q3-2002Q2	139
Figure 3.86:	Diagnostics - key companies, 2001Q3-2002Q2	141
Figure 3.87:	Diagnostics - deal-making by company type, 2001Q3-2002Q2	142
Figure 3.88:	Diagnostics – level of collaboration, 2001Q3-2002Q2	142
Figure 3.89:	Diagnostics - stage of alliance, 2001Q3-2002Q2	143
Figure 3.90:	Diagnostics - technology, 2001Q3-2002Q2	143
Figure 3.91:	Diagnostics - therapy areas, 2001Q3-2002Q2	144
Figure 3.92:	Equipment & devices - key companies, 2001Q3-2002Q2	147
Figure 3.93:	Equipment & devices - deal-making by company type, 2001Q3-2002Q2	147
Figure 3.94:	Equipment & devices – level of collaboration, 2001Q3-2002Q2	148

Figure 3.95:	Equipment & devices - stage of alliance, 2001Q3-2002Q2	148
Figure 3.96:	Equipment & devices - technology, 2001Q3-2002Q2	149
Figure 3.97:	Equipment & devices - therapy areas, 2001Q3-2002Q2	149
Figure 3.98:	Other therapy areas, 2001Q3-2002Q2	150
Figure 4.99:	Key technologies, 2001Q3-2002Q2	156
Figure 4.100:	Average deal value by technology, 2001Q3-2002Q2	157
Figure 4.101:	Technology - key companies, 2001Q3-2002Q2	158
Figure 4.102:	Technology - deal-making by company type, 2001Q3-2002Q2	159
Figure 4.103:	Technology – level of collaboration, 2001Q3-2002Q2	160
Figure 4.104:	Technology - stage of alliance, 2001Q3-2002Q2	160
Figure 4.105:	Technology - therapy area, 2001Q3-2002Q2	161
Figure 4.106:	Genomics - key companies, 2001Q3-2002Q2	164
Figure 4.107:	Genomics - deal-making by company type, 2001Q3-2002Q2	164
Figure 4.108:	Genomics – level of collaboration, 2001Q3-2002Q2	165
Figure 4.109:	Genomics - stage of alliance, 2001Q3-2002Q2	165
Figure 4.110:	Genomics – therapy area, 2001Q3-2002Q2	166
Figure 4.111:	Standard platforms - key companies, 2001Q3-2002Q2	168
Figure 4.112:	Standard platforms - deal-making by company type, 2001Q3-2002Q2	169
Figure 4.113:	Standard platforms – level of collaboration, 2001Q3-2002Q2	169
Figure 4.114:	Standard platforms - stage of alliance, 2001Q3-2002Q2	170
Figure 4.115:	Standard platforms – therapy area, 2001Q3-2002Q2	170
Figure 4.116:	Drug delivery - key companies, 2001Q3-2002Q2	172
Figure 4.117:	Drug delivery - deal-making by company type, 2001Q3-2002Q2	173
Figure 4.118:	Drug delivery – level of collaboration, 2001Q3-2002Q2	174
Figure 4.119:	Drug delivery - stage of alliance, 2001Q3-2002Q2	175
Figure 4.120:	Drug delivery – therapy area, 2001Q3-2002Q2	176
Figure 4.121:	Proteomics - key companies, 2001Q3-2002Q2	179
Figure 4.122:	Proteomics - deal-making by company type, 2001Q3-2002Q2	180
Figure 4.123:	Proteomics – level of collaboration, 2001Q3-2002Q2	180
Figure 4.124:	Proteomics - stage of alliance, 2001Q3-2002Q2	181
Figure 4.125:	Proteomics – therapy area, 2001Q3-2002Q2	181
Figure 4.126:	Bioinformatics - key companies, 2001Q3-2002Q2	184
Figure 4.127:	Bioinformatics - deal-making by company type, 2001Q3-2002Q2	184
Figure 4.128:	Bioinformatics – level of collaboration, 2001Q3-2002Q2	185
Figure 4.129:	Bioinformatics - stage of alliance, 2001Q3-2002Q2	185
Figure 4.130:	Bioinformatics – therapy area, 2001Q3-2002Q2	186
Figure 4.131:	Gene/cell therapy - key companies, 2001Q3-2002Q2	189
Figure 4.132:	Gene/cell therapy - deal-making by company type, 2001Q3-2002Q2	190
Figure 4.133:	Gene/cell therapy – level of collaboration, 2001Q3-2002Q2	190
Figure 4.134:	Gene/cell therapy - stage of alliance, 2001Q3-2002Q2	191
Figure 4.135:	Gene/cell therapy – therapy area, 2001Q3-2002Q2	191
Figure 4.136:	Pharmacogenomics - key companies, 2001Q3-2002Q2	192
Figure 4.137:	Pharmacogenomics - deal-making by company type, 2001Q3-2002Q2	193
Figure 4.138:	Pharmacogenomics – level of collaboration, 2001Q3-2002Q2	193
Figure 4.139:	Pharmacogenomics - stage of alliance, 2001Q3-2002Q2	194
Figure 4.140:	Pharmacogenomics – therapy area, 2001Q3-2002Q2	194
Figure 5.141:	Alliance partners - key companies, 2001Q3-2002Q2	200
Figure 5.142:	Alliance partners - deal-making companies, 2001Q3-2002Q2	201
Figure 5.143:	Alliance partners - deal-making by company type, 2001Q3-2002Q2	202
Figure 5.144:	Average deal value by company type, 2001Q3-2002Q2	203
Figure 5.145:	Pharmaceutical/pharmaceutical - key companies, 2001Q3-2002Q2	205
Figure 5.146:	Pharmaceutical/pharmaceutical – level of collaboration, 2001Q3-2002Q2	205
Figure 5.147:	Pharmaceutical/pharmaceutical - stage of alliance, 2001Q3-2002Q2	206

Figure 5.148:	Pharmaceutical/pharmaceutical – therapy areas, 2001Q3-2002Q2	207
Figure 5.149:	Pharmaceutical/pharmaceutical - technology, 2001Q3-2002Q2	207
Figure 5.150:	Pharmaceutical/biotechnology - key pharma companies, 2001Q3-2002Q2	211
Figure 5.151:	Pharmaceutical/biotechnology - key biotech companies, 2001Q3-2002Q2	212
Figure 5.152:	Pharmaceutical/biotechnology – level of collaboration, 2001Q3-2002Q2	213
Figure 5.153:	Pharmaceutical/biotechnology - stage of alliance, 2001Q3-2002Q2	214
Figure 5.154:	Pharmaceutical/biotechnology – therapy areas, 2001Q3-2002Q2	215
Figure 5.155:	Pharmaceutical/biotechnology - technology, 2001Q3-2002Q2	216
Figure 5.156:	Biotechnology/biotechnology - key companies, 2001Q3-2002Q2	218
Figure 5.157:	Biotechnology/biotechnology – level of collaboration, 2001Q3-2002Q2	219
Figure 5.158:	Biotechnology/biotechnology - stage of alliance, 2001Q3-2002Q2	220
Figure 5.159:	Biotechnology/biotechnology – therapy areas, 2001Q3-2002Q2	221
Figure 5.160:	Biotechnology/biotechnology - technology, 2001Q3-2002Q2	222
Figure 5.161:	Drug delivery - key drug delivery companies, 2001Q3-2002Q2	225
Figure 5.162:	Drug delivery - key partner companies, 2001Q3-2002Q2	225
Figure 5.163:	Drug delivery – deal-making by company type, 2001Q3-2002Q2	226
Figure 5.164:	Drug delivery – level of collaboration, 2001Q3-2002Q2	227
Figure 5.165:	Drug delivery - stage of alliance, 2001Q3-2002Q2	228
Figure 5.166:	Drug delivery – therapy areas, 2001Q3-2002Q2	229
Figure 5.167:	Drug delivery - technology, 2001Q3-2002Q2	230
Figure 5.168:	Academia/NGO - key academia/NGO institutions, 2001Q3-2002Q2	233
Figure 5.169:	Academia/NGO - key partner companies, 2001Q3-2002Q2	234
Figure 5.170:	Academia/NGO – deal-making by company type, 2001Q3-2002Q2	234
Figure 5.171:	Academia/NGO – level of collaboration, 2001Q3-2002Q2	235
Figure 5.172:	Academia/NGO - stage of alliance, 2001Q3-2002Q2	235
Figure 5.173:	Academia/NGO – therapy areas, 2001Q3-2002Q2	236
Figure 5.174:	Academia/NGO - technology, 2001Q3-2002Q2	237
Figure 5.175:	Diagnostics - key diagnostic companies, 2001Q3-2002Q2	240
Figure 5.176:	Diagnostics - key partner companies, 2001Q3-2002Q2	240
Figure 5.177:	Diagnostics – deal-making by company type, 2001Q3-2002Q2	241
Figure 5.178:	Diagnostics – level of collaboration, 2001Q3-2002Q2	242
Figure 5.179:	Diagnostics - stage of alliance, 2001Q3-2002Q2	243
Figure 5.180:	Diagnostics – therapy areas, 2001Q3-2002Q2	244
Figure 5.181:	Diagnostics - technology, 2001Q3-2002Q2	244
Figure 5.182:	Equipment & devices - key equipment & device companies, 2001Q3-2002Q2	247
Figure 5.183:	Equipment & devices - key partner companies, 2001Q3-2002Q2	247
Figure 5.184:	Equipment & devices – deal-making by company type, 2001Q3-2002Q2	248
Figure 5.185:	Equipment & devices – level of collaboration, 2001Q3-2002Q2	249
Figure 5.186:	Equipment & devices - stage of alliance, 2001Q3-2002Q2	249
Figure 5.187:	Equipment & devices – therapy areas, 2001Q3-2002Q2	250
Figure 5.188:	Equipment & devices - technology, 2001Q3-2002Q2	250
Figure 5.189:	Other partnerships, 2001Q3-2002Q2	251
Figure 6.190:	Trends - alliance type by quarter, 2001Q3-2002Q2	256
Figure 6.191:	Trends - alliance type distribution by quarter, 2001Q3-2002Q2	257
Figure 6.192:	Trends – therapy area by quarter, 2001Q3-2002Q2	259
Figure 6.193:	Trends – therapy area distribution by quarter, 2001Q3-2002Q2	260
Figure 6.194:	Trends - technology by quarter, 2001Q3-2002Q2	263
Figure 6.195:	Trends - technology distribution by quarter, 2001Q3-2002Q2	264
Figure 6.196:	Trends - company type by quarter, 2001Q3-2002Q2	267
Figure 6.197:	Trends - company type distribution by quarter, 2001Q3-2002Q2	268

List of Tables

Table 1.1:	Average and maximum alliance value, 2000Q1-2002Q2	31
Table 1.2:	Top 10 relationship alliances by value, 2000Q1-2002Q2	32
Table 1.3:	Top 5 transaction alliances by value, 2000Q1-2002Q2	45
Table 1.4:	Alliances by company type, 2000Q1-2002Q2	50
Table 2.5:	Acquisition - top 5 alliances by value, 2001Q3-2002Q2	61
Table 2.6:	Transaction licensing - top 5 alliances by value, 2001Q3-2002Q2	67
Table 2.7:	Relationship licensing - top 5 alliances by value, 2001Q3-2002Q2	74
Table 2.8:	Co-development - top 5 alliances by value, 2001Q3-2002Q2	80
Table 2.9:	Co-commercialization - top 5 alliances by value, 2001Q3-2002Q2	87
Table 2.10:	Other alliance types - top 10 alliances by value, 2001Q3-2002Q2	93
Table 3.11:	Therapy area - top 5 alliances by value, 2001Q3-2002Q2	101
Table 3.12:	Oncology - top 5 alliances by value, 2001Q3-2002Q2	105
Table 3.13:	Infectious & viral diseases - top 5 alliances by value, 2001Q3-2002Q2	110
Table 3.14:	Central nervous system - top 5 alliances by value, 2001Q3-2002Q2	115
Table 3.15:	Cardiovascular - top 5 alliances by value, 2001Q3-2002Q2	120
Table 3.16:	Musculoskeletal & inflammation - top 5 alliances by value, 2001Q3-2002Q2	125
Table 3.17:	Metabolic - top 5 alliances by value, 2001Q3-2002Q2	130
Table 3.18:	Vaccines - top 5 alliances by value, 2001Q3-2002Q2	135
Table 3.19:	Diagnostics - top 5 alliances by value, 2001Q3-2002Q2	140
Table 3.20:	Equipment & devices - top 5 alliances by value, 2001Q3-2002Q2	145
Table 3.21:	Other alliance types - top 10 alliances by value, 2001Q3-2002Q2	151
Table 4.22:	Technology - top 5 alliances by value, 2001Q3-2002Q2	157
Table 4.23:	Genomics - top 5 alliances by value, 2001Q3-2002Q2	162
Table 4.24:	Standard platforms - top 5 alliances by value, 2001Q3-2002Q2	167
Table 4.25:	Drug delivery - top 5 alliances by value, 2001Q3-2002Q2	171
Table 4.26:	Proteomics - top 5 alliances by value, 2001Q3-2002Q2	177
Table 4.27:	Bioinformatics - top 4 alliances by value, 2001Q3-2002Q2	182
Table 4.28:	Gene/cell therapy - top 5 alliances by value, 2001Q3-2002Q2	187
Table 4.29:	Other technology - top 10 alliances by value, 2001Q3-2002Q2	195
Table 5.30:	Pharmaceutical/pharmaceutical - top 5 alliances by value, 2001Q3-2002Q2	204
Table 5.31:	Pharmaceutical/biotechnology - top 5 alliances by value, 2001Q3-2002Q2	209
Table 5.32:	Biotechnology/biotechnology - top 5 alliances by value, 2001Q3-2002Q2	217
Table 5.33:	Drug delivery - top 5 alliances by value, 2001Q3-2002Q2	223
Table 5.34:	Academia/NGO - top 5 alliances by value, 2001Q3-2002Q2	231
Table 5.35:	Diagnostics - top 3 alliances by value, 2001Q3-2002Q2	238
Table 5.36:	Equipment & devices - top 5 alliances by value, 2001Q3-2002Q2	245
Table 5.37:	Other partnerships - top 5 alliances by value, 2001Q3-2002Q2	251